| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Very Low Birth Weight | 11 | 2025 | 21 | 2.830 |
Why?
|
| Infant, Newborn | 47 | 2025 | 1479 | 2.350 |
Why?
|
| Infant, Premature, Diseases | 7 | 2025 | 19 | 1.860 |
Why?
|
| Hypoxia-Ischemia, Brain | 4 | 2025 | 21 | 1.820 |
Why?
|
| Infant, Newborn, Diseases | 7 | 2021 | 73 | 1.710 |
Why?
|
| Hypothermia, Induced | 4 | 2024 | 17 | 1.660 |
Why?
|
| Retrospective Studies | 19 | 2025 | 799 | 1.600 |
Why?
|
| Infant Mortality | 5 | 2024 | 97 | 1.550 |
Why?
|
| Developing Countries | 10 | 2024 | 400 | 1.250 |
Why?
|
| Neonatal Sepsis | 5 | 2024 | 29 | 1.240 |
Why?
|
| Humans | 69 | 2025 | 14537 | 1.210 |
Why?
|
| South Africa | 39 | 2025 | 7596 | 1.190 |
Why?
|
| Developmental Disabilities | 3 | 2020 | 22 | 1.170 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2023 | 3 | 1.130 |
Why?
|
| Female | 48 | 2025 | 9103 | 1.120 |
Why?
|
| Infant | 20 | 2023 | 2244 | 1.040 |
Why?
|
| Child Development | 3 | 2020 | 93 | 1.030 |
Why?
|
| Male | 35 | 2025 | 6754 | 0.950 |
Why?
|
| Tertiary Care Centers | 3 | 2023 | 80 | 0.950 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2024 | 17 | 0.940 |
Why?
|
| Birth Weight | 8 | 2024 | 80 | 0.940 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2021 | 529 | 0.900 |
Why?
|
| Infant, Premature | 8 | 2025 | 56 | 0.840 |
Why?
|
| Cerebral Palsy | 2 | 2020 | 12 | 0.750 |
Why?
|
| HIV Infections | 5 | 2023 | 5097 | 0.720 |
Why?
|
| Critical Care | 3 | 2018 | 52 | 0.710 |
Why?
|
| Language Development Disorders | 2 | 2020 | 2 | 0.700 |
Why?
|
| Risk Factors | 11 | 2025 | 1475 | 0.690 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2024 | 37 | 0.680 |
Why?
|
| Hospitalization | 3 | 2019 | 418 | 0.660 |
Why?
|
| Sepsis | 6 | 2023 | 102 | 0.650 |
Why?
|
| Clinical Audit | 1 | 2019 | 3 | 0.640 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 11 | 0.630 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2019 | 1 | 0.630 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 472 | 0.630 |
Why?
|
| Survival Rate | 3 | 2020 | 96 | 0.620 |
Why?
|
| Critical Illness | 2 | 2016 | 44 | 0.610 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2018 | 4 | 0.600 |
Why?
|
| Growth Disorders | 1 | 2019 | 56 | 0.600 |
Why?
|
| Pregnancy | 12 | 2023 | 1862 | 0.600 |
Why?
|
| Pediatrics | 1 | 2018 | 17 | 0.590 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1422 | 0.590 |
Why?
|
| Hodgkin Disease | 3 | 2023 | 11 | 0.590 |
Why?
|
| Hospital Mortality | 1 | 2018 | 95 | 0.580 |
Why?
|
| Asphyxia | 1 | 2017 | 5 | 0.560 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2017 | 1 | 0.540 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 5 | 0.540 |
Why?
|
| Heart | 1 | 2017 | 27 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 27 | 0.530 |
Why?
|
| Hyaline Membrane Disease | 5 | 2015 | 5 | 0.510 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 253 | 0.510 |
Why?
|
| Patient Discharge | 1 | 2016 | 27 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 293 | 0.480 |
Why?
|
| Prospective Studies | 10 | 2023 | 1160 | 0.480 |
Why?
|
| Antifungal Agents | 2 | 2023 | 40 | 0.450 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 5 | 0.450 |
Why?
|
| Candida | 2 | 2023 | 24 | 0.450 |
Why?
|
| Pulmonary Surfactants | 5 | 2015 | 8 | 0.420 |
Why?
|
| Candidiasis | 1 | 2013 | 15 | 0.410 |
Why?
|
| Candidemia | 1 | 2013 | 13 | 0.410 |
Why?
|
| Klebsiella pneumoniae | 2 | 2024 | 39 | 0.370 |
Why?
|
| Cause of Death | 3 | 2019 | 221 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 198 | 0.350 |
Why?
|
| Child | 9 | 2023 | 2242 | 0.330 |
Why?
|
| Hospitals | 2 | 2021 | 103 | 0.310 |
Why?
|
| Sentinel Surveillance | 2 | 2020 | 115 | 0.310 |
Why?
|
| Fluconazole | 2 | 2023 | 17 | 0.310 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 370 | 0.280 |
Why?
|
| Patient Selection | 3 | 1996 | 40 | 0.270 |
Why?
|
| Adolescent | 11 | 2023 | 2985 | 0.270 |
Why?
|
| Case-Control Studies | 4 | 2024 | 480 | 0.250 |
Why?
|
| Streptococcus agalactiae | 3 | 2015 | 202 | 0.250 |
Why?
|
| Streptococcal Infections | 3 | 2015 | 184 | 0.240 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2025 | 2 | 0.230 |
Why?
|
| Cerebral Hemorrhage | 1 | 2025 | 8 | 0.230 |
Why?
|
| Calcitonin | 1 | 2004 | 10 | 0.230 |
Why?
|
| Protein Precursors | 1 | 2004 | 22 | 0.220 |
Why?
|
| Antibodies, Bacterial | 2 | 2015 | 153 | 0.220 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2024 | 7 | 0.220 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 15 | 0.220 |
Why?
|
| Logistic Models | 3 | 2012 | 254 | 0.220 |
Why?
|
| Acinetobacter baumannii | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cross Infection | 1 | 2024 | 52 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2013 | 889 | 0.220 |
Why?
|
| Serratia marcescens | 2 | 2024 | 3 | 0.220 |
Why?
|
| Enterobacter cloacae | 2 | 2024 | 3 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 176 | 0.220 |
Why?
|
| Escherichia coli | 2 | 2024 | 30 | 0.210 |
Why?
|
| Syphilis, Congenital | 2 | 1993 | 13 | 0.210 |
Why?
|
| Candidiasis, Invasive | 1 | 2023 | 3 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 21 | 0.200 |
Why?
|
| Prevalence | 2 | 2025 | 1192 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2021 | 57 | 0.180 |
Why?
|
| Gestational Age | 4 | 2024 | 80 | 0.180 |
Why?
|
| Risk | 2 | 2018 | 87 | 0.180 |
Why?
|
| Food, Fortified | 3 | 1989 | 11 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2023 | 967 | 0.170 |
Why?
|
| Hospitals, Public | 3 | 2010 | 45 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2019 | 179 | 0.170 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 34 | 0.170 |
Why?
|
| Health Personnel | 2 | 2020 | 231 | 0.170 |
Why?
|
| Proteus mirabilis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Klebsiella | 1 | 2019 | 6 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 14 | 0.160 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 6 | 0.160 |
Why?
|
| Growth Charts | 1 | 2019 | 4 | 0.160 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 13 | 0.160 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2019 | 3 | 0.160 |
Why?
|
| Neonatal Screening | 1 | 2019 | 24 | 0.160 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2019 | 5 | 0.160 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 284 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 57 | 0.150 |
Why?
|
| Drug Resistance, Fungal | 2 | 2023 | 13 | 0.150 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2019 | 108 | 0.150 |
Why?
|
| Income | 1 | 2019 | 85 | 0.150 |
Why?
|
| Ferric Compounds | 2 | 1989 | 5 | 0.150 |
Why?
|
| Edetic Acid | 2 | 1989 | 8 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 22 | 0.150 |
Why?
|
| Patient Admission | 1 | 2018 | 11 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 69 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2018 | 64 | 0.150 |
Why?
|
| Comorbidity | 1 | 2019 | 188 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2019 | 1748 | 0.150 |
Why?
|
| Data Collection | 1 | 2018 | 86 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 239 | 0.140 |
Why?
|
| Iron | 5 | 1988 | 32 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2017 | 2 | 0.140 |
Why?
|
| Echocardiography | 1 | 2017 | 100 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2016 | 325 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 65 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2015 | 149 | 0.130 |
Why?
|
| Child Health Services | 1 | 1996 | 35 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2016 | 55 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 1996 | 52 | 0.120 |
Why?
|
| Medical Records | 2 | 2019 | 23 | 0.120 |
Why?
|
| Obstetric Labor, Premature | 1 | 1995 | 6 | 0.120 |
Why?
|
| Incidence | 2 | 2019 | 685 | 0.120 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1995 | 21 | 0.120 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 33 | 0.120 |
Why?
|
| Biological Products | 1 | 1995 | 7 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 188 | 0.120 |
Why?
|
| Research Design | 1 | 2016 | 124 | 0.120 |
Why?
|
| ROC Curve | 2 | 2024 | 51 | 0.110 |
Why?
|
| Brain Injuries | 1 | 1993 | 3 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 231 | 0.110 |
Why?
|
| Hypoxia | 1 | 1993 | 12 | 0.110 |
Why?
|
| Asphyxia Neonatorum | 1 | 1993 | 11 | 0.100 |
Why?
|
| Voriconazole | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hemochromatosis | 3 | 1988 | 5 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 20 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 411 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 32 | 0.100 |
Why?
|
| Speech Disorders | 1 | 1992 | 1 | 0.100 |
Why?
|
| Hearing Disorders | 1 | 1992 | 3 | 0.100 |
Why?
|
| Sex Factors | 2 | 2010 | 227 | 0.100 |
Why?
|
| Prenatal Care | 4 | 2020 | 147 | 0.090 |
Why?
|
| Intensive Care, Neonatal | 1 | 2012 | 4 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 83 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 171 | 0.090 |
Why?
|
| Biomarkers | 3 | 2015 | 327 | 0.090 |
Why?
|
| Body Weight | 1 | 2011 | 111 | 0.090 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1987 | 5 | 0.090 |
Why?
|
| Adult | 11 | 2019 | 5913 | 0.090 |
Why?
|
| Hypotension | 1 | 2010 | 7 | 0.080 |
Why?
|
| Time Factors | 2 | 2010 | 507 | 0.080 |
Why?
|
| Mass Screening | 3 | 2020 | 245 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 133 | 0.080 |
Why?
|
| Animals | 4 | 2025 | 1081 | 0.080 |
Why?
|
| Public Sector | 1 | 2010 | 82 | 0.080 |
Why?
|
| Nutrition Surveys | 1 | 1989 | 13 | 0.080 |
Why?
|
| Ferritins | 5 | 1989 | 23 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 199 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 1988 | 1 | 0.070 |
Why?
|
| Opium | 1 | 1988 | 1 | 0.070 |
Why?
|
| Apnea | 1 | 1988 | 2 | 0.070 |
Why?
|
| Nutritional Status | 1 | 1989 | 76 | 0.070 |
Why?
|
| Pandemics | 2 | 2020 | 296 | 0.070 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 1987 | 1 | 0.070 |
Why?
|
| Ureteral Obstruction | 1 | 1987 | 3 | 0.070 |
Why?
|
| Oryza | 1 | 1987 | 3 | 0.070 |
Why?
|
| Fruit | 1 | 1987 | 5 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1987 | 32 | 0.070 |
Why?
|
| Beverages | 1 | 1987 | 42 | 0.070 |
Why?
|
| Erythropoietin | 2 | 2002 | 8 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 385 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1987 | 115 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2004 | 4 | 0.060 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2004 | 8 | 0.060 |
Why?
|
| Platelet Count | 1 | 2004 | 14 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 18 | 0.060 |
Why?
|
| Parents | 1 | 2004 | 32 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2004 | 43 | 0.060 |
Why?
|
| Fosfomycin | 1 | 2024 | 1 | 0.060 |
Why?
|
| Amikacin | 1 | 2024 | 7 | 0.060 |
Why?
|
| beta-Lactamases | 1 | 2024 | 23 | 0.050 |
Why?
|
| Bacteremia | 1 | 2004 | 79 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2023 | 1 | 0.050 |
Why?
|
| Vinblastine | 1 | 2023 | 1 | 0.050 |
Why?
|
| Bleomycin | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vincristine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 17 | 0.050 |
Why?
|
| Counseling | 1 | 2004 | 143 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 106 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 33 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 279 | 0.050 |
Why?
|
| Carbapenems | 1 | 2023 | 17 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 119 | 0.050 |
Why?
|
| Candida parapsilosis | 1 | 2023 | 4 | 0.050 |
Why?
|
| C-Reactive Protein | 2 | 2000 | 96 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 6 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 25 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 26 | 0.050 |
Why?
|
| Candida albicans | 1 | 2023 | 15 | 0.050 |
Why?
|
| Anemia, Neonatal | 1 | 2002 | 2 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2002 | 6 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2002 | 35 | 0.050 |
Why?
|
| African Americans | 1 | 2002 | 47 | 0.050 |
Why?
|
| Young Adult | 2 | 2019 | 2498 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 125 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 51 | 0.040 |
Why?
|
| Altruism | 1 | 2020 | 7 | 0.040 |
Why?
|
| Professionalism | 1 | 2020 | 5 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Research | 1 | 2020 | 65 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.040 |
Why?
|
| India | 2 | 1989 | 62 | 0.040 |
Why?
|
| Motor Disorders | 1 | 2018 | 1 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 135 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 13 | 0.040 |
Why?
|
| Age Factors | 3 | 1989 | 370 | 0.040 |
Why?
|
| Anemia, Hypochromic | 2 | 1989 | 2 | 0.040 |
Why?
|
| Global Health | 1 | 2019 | 193 | 0.040 |
Why?
|
| Aged | 3 | 1987 | 1740 | 0.040 |
Why?
|
| Hemoglobins | 2 | 1989 | 40 | 0.040 |
Why?
|
| Reference Values | 3 | 2002 | 64 | 0.030 |
Why?
|
| HLA Antigens | 2 | 1988 | 50 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 563 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 321 | 0.030 |
Why?
|
| Apgar Score | 1 | 1996 | 8 | 0.030 |
Why?
|
| Uncertainty | 1 | 2016 | 7 | 0.030 |
Why?
|
| Hospitals, Private | 1 | 1996 | 8 | 0.030 |
Why?
|
| Solid Phase Microextraction | 1 | 2016 | 2 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 237 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 156 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2016 | 24 | 0.030 |
Why?
|
| Medical Audit | 1 | 1995 | 26 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 1995 | 16 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1995 | 47 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1995 | 59 | 0.030 |
Why?
|
| Erythema Infectiosum | 1 | 1994 | 1 | 0.030 |
Why?
|
| Parvovirus B19, Human | 1 | 1994 | 5 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 24 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1994 | 24 | 0.030 |
Why?
|
| Middle Aged | 5 | 1988 | 3601 | 0.030 |
Why?
|
| Free Radicals | 1 | 1993 | 6 | 0.030 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 1993 | 2 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 27 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1993 | 23 | 0.030 |
Why?
|
| Models, Biological | 1 | 1993 | 77 | 0.030 |
Why?
|
| United States | 1 | 1993 | 132 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 1994 | 117 | 0.030 |
Why?
|
| Rubella | 1 | 1993 | 5 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1993 | 23 | 0.020 |
Why?
|
| Language Development | 1 | 1992 | 4 | 0.020 |
Why?
|
| Pedigree | 2 | 1988 | 30 | 0.020 |
Why?
|
| Absorption | 2 | 1987 | 6 | 0.020 |
Why?
|
| Citrates | 2 | 1987 | 4 | 0.020 |
Why?
|
| Heterozygote | 2 | 1988 | 43 | 0.020 |
Why?
|
| Ascorbic Acid | 2 | 1987 | 13 | 0.020 |
Why?
|
| Citric Acid | 2 | 1987 | 8 | 0.020 |
Why?
|
| Homozygote | 2 | 1988 | 61 | 0.020 |
Why?
|
| Zinc | 1 | 1989 | 10 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1989 | 64 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 112 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1989 | 272 | 0.020 |
Why?
|
| Condiments | 1 | 1987 | 1 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1987 | 10 | 0.020 |
Why?
|
| Phenotype | 1 | 1988 | 158 | 0.020 |
Why?
|
| Soybeans | 1 | 1987 | 1 | 0.020 |
Why?
|
| Transferrin | 1 | 1987 | 5 | 0.020 |
Why?
|
| Nutritive Value | 1 | 1987 | 4 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 13 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 30 | 0.010 |
Why?
|
| Resuscitation | 1 | 2004 | 18 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 43 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 53 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 225 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 22 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 45 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 73 | 0.010 |
Why?
|
| Fetal Hemoglobin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2002 | 15 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2002 | 11 | 0.010 |
Why?
|
| Penicillins | 1 | 2001 | 25 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 38 | 0.010 |
Why?
|
| Genetic Linkage | 2 | 1988 | 8 | 0.010 |
Why?
|
| Gene Frequency | 2 | 1988 | 122 | 0.010 |
Why?
|
| Cost Savings | 1 | 1995 | 7 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1995 | 4 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1995 | 13 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1994 | 109 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 1993 | 22 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1993 | 26 | 0.010 |
Why?
|
| Carrier State | 1 | 1993 | 92 | 0.010 |
Why?
|
| Gastric Acid | 1 | 1987 | 1 | 0.000 |
Why?
|
| Solanum tuberosum | 1 | 1987 | 1 | 0.000 |
Why?
|
| Milk | 1 | 1987 | 1 | 0.000 |
Why?
|
| Soybean Proteins | 1 | 1987 | 1 | 0.000 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1987 | 6 | 0.000 |
Why?
|
| Infant Food | 1 | 1987 | 4 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 130 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1987 | 28 | 0.000 |
Why?
|
| Diet | 1 | 1987 | 109 | 0.000 |
Why?
|